Critical Cancer Research - on demand
Time-sensitive and reliable cancer news, research and analysis
covering clinical trials, drugs, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients and their family.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €720/£720 a year per user. This works out at €60/£60 a month per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients/Family
Patients/family can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
- 2. A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- 3. NeoTIL in Advanced Solid Tumors
- 4. Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
- 5. BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
- 6. Boris must make biggest call of his political career
- 7. Dealing with Hormonal Imbalance? Femarelle® Will Rejuvenate Your Life
- 8. Novartis set to overcome $14 billion patent cliff say analysts
- 9. Could the TB Vaccine Help Prevent COVID-19?
- 10. What are the biggest issues in drug discovery and development?
Last updated at 6:19 GMT
Hot News Makers
Health/Pharma Companies
-
37398.34
-
13271.62
-
10508.45
-
9007.24
-
6394.26
-
5778.31
-
3879.14
-
3584.73
-
2696.41
-
2584.02
Last updated at 6:10 GMT
© Copyright 2020 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK